Likewise, the prognostic impact of hormone receptor status in endometrial tumor tissue is well documented [26–28], and easily assessed by immunohistochemistry, however not applied in the routine diagnostic setting either. This evidence concerns the gene NR4A1 and endometrium neoplasm.